
GLP-1 Drugs: 2024 Pulse Survey Report (U.S. data)

A new survey report from the International Foundation reveals updated U.S. employer coverage surrounding glucagon-like peptide-1 (GLP-1) drugs. The data also provides a snapshot of other approaches used by employers that offer health care coverage to address certain chronic health conditions.
The graphs below reflect corporate plan responses

The following are results from organizations that offer GLP-1 drugs for weight loss.

*Respondents were asked to select all that apply.

There's more! View a full listing of International Foundation benchmarking and pulse survey reports.
Survey reports are just one of the many helpful products and services included with an International Foundation membership.